Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance

• Main Authors: DC Whitacre (Author), CJ Peters (Author), C Sureau (Author), K Nio (Author), F Li (Author), L Su (Author), JE Jones (Author), M Isogawa (Author), M Sallberg (Author), L Frelin (Author), DL Peterson (Author), DR Milich (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

An effective prophylactic hepatitis B virus (HBV) vaccine has long been available but is ineffective for chronic infection. The primary cause of chronic hepatitis B (CHB) and greatest impediment for a therapeutic vaccine is the direct and indirect effects of immune tolerance to HBV antigens. The res...